HCC支持数据和毒性管理的免疫治疗现状

StephenW

Current Hepatology Reports

December 2018, Volume 17, Issue 4, pp 434–443 | Cite as
Current State of Immunotherapy for HCC—Supporting Data and Toxicity Management

    Authors
    Authors and affiliations

    Anthony BejjaniRichard S. FinnEmail author

    Anthony Bejjani
        1
    Richard S. Finn
        1Email author

    1.Department of Medicine, Division of Hematology and OncologyGeffen School of Medicine at UCLALos AngelesUSA

Hepatic Cancer (A Singal and A Mufti, Section Editors)
First Online: 28 October 2018

    55 Downloads

Part of the following topical collections:

    Topical Collection on Hepatic Cancer

Abstract
Purpose of Review

After having tyrosine kinase inhibitor as only available one drug class to treat advanced hepatocellular carcinoma (HCC) for more than a decade, immunotherapy agents are now approved for second-line therapy and are currently being compared head-to-head with sorafenib for first-line treatment. It is becoming increasingly important for hepatologists to become aware of agents in development, potential adverse events, and suggested treatment monitoring.
Recent Findings

Nivolumab and pembrolizumab have both shown promising phase II data in the second-line setting for HCC and phase III data in both the first-line and second-line settings are anticipated soon. Durable responses of 15–20% is seen as a potential breakthrough and may translate into improved survival for patients with advanced HCC. While immunotherapies are well tolerated overall, rare but serious immune-mediated adverse events are possible and warrant monitoring to facilitate early treatment when needed. There is ongoing research of combinations with immunotherapy agents and other systemic agents and/or locoregional therapies to further enhance response rates.
Summary

Ongoing studies will define the role of immunotherapy for treatment of HCC, both as single agents as well as in combination with other therapies.
Keywords
Hepatocellular carcinoma HCC Immunotherapy Checkpoint blockade PD-1 PD-L1 Nivolumab Pembrolizumab Atezolizumab Durvalumab CTLA-4

This article is part of the Topical Collection on Hepatic Cancer

StephenW

目前的肝病学报告

2018年12月，第17卷，第4期，第434-443页引用为
HCC支持数据和毒性管理的免疫治疗现状

    作者
    作者和附属机构

    Anthony BejjaniRichard S. Finn的电子书作者

    安东尼Bejjani
        1
    理查德S.芬恩
        1电子邮件作者

    1.美国加州大学洛杉矶分校美国医学院血液学和肿瘤学系

肝癌（Singal和A Mufti，部门编辑）
首次在线：2018年10月28日

    55下载

以下主题集合的一部分：

    关于肝癌的专题收集

抽象
审查目的

在使用酪氨酸激酶抑制剂作为治疗晚期肝细胞癌（HCC）十多年的唯一药物类别后，免疫治疗药物现已被批准用于二线治疗，目前正与索拉非尼首次进行头对头比较 - 线路治疗。对于肝病学家来说，了解发育中的药剂，潜在的不良事件以及建议的治疗监测变得越来越重要。
最近的调查结果

Nivolumab和pembrolizumab在HCC的二线设置中均显示出有希望的II期数据，并且很快就会在第一线和第二线设置中显示III期数据。 15-20％的持久反应被视为潜在的突破，可能转化为晚期HCC患者的生存率提高。尽管免疫疗法总体上耐受良好，但是罕见但严重的免疫介导的不良事件是可能的，并且需要监测以在需要时促进早期治疗。目前正在进行与免疫治疗剂和其他全身性药剂和/或局部治疗的组合的研究，以进一步提高应答率。
摘要

正在进行的研究将确定免疫疗法在治疗HCC中的作用，既可作为单一药物，也可与其他疗法联合使用。
关键词
肝细胞癌HCC免疫治疗检查点阻滞PD-1 PD-L1 Nivolumab Pembrolizumab Atezolizumab Durvalumab CTLA-4

本文是肝癌专题收集的一部分